Proteasome Subunits Involved in Neurodegenerative Diseases

被引:27
|
作者
Fernandez-Cruz, Ivan [1 ]
Reynaud, Enrique [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Genet Desarrollo & Fisiol Mol, Ave Univ 2001, Cuernavaca 62218, Morelos, Mexico
关键词
Proteasome subunits; Parkinson's disease; Alzheimer's disease; Huntington's disease; Amyotrophic lateral sclerosis; Spinocerebellar ataxia;
D O I
10.1016/j.arcmed.2020.09.007
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The ubiquitin-proteasome system is the major pathway for the maintenance of protein homeostasis. Its inhibition causes accumulation of ubiquitinated proteins; this accumulation has been associated with several of the most common neurodegenerative diseases. Several genetic factors have been identified for most neurodegenerative diseases, however, most cases are considered idiopathic, thus making the study of the mechanisms of protein accumulation a relevant field of research. It is often mentioned that the biggest risk factor for neurodegenerative diseases is aging, and several groups have reported an age-related alteration of the expression of some of the 26S proteasome subunits and a reduction of its activity. Proteasome subunits interact with proteins that are known to accumulate in neurodegenerative diseases such as alpha-synuclein in Parkinson's, tau in Alzheimer's, and huntingtin in Huntington's diseases. These interactions have been explored for several years, but only until recently, we are beginning to understand them. In this review, we discuss the known interactions, the underlying patterns, and the phenotypes associated with the 26S proteasome subunits in the etiology and progression of neurodegenerative diseases where there is evidence of proteasome involvement. Special emphasis is made in reviewing proteasome subunits that interact with proteins known to have an age related altered expression or to be involved in neurodegenerative diseases to explore key effectors that may trigger or augment their progression. Interestingly, while the causes of age-related reduction of some of the proteasome subunits are not known, there are specific relationships between the observed neurodegenerative disease and the affected proteasome subunits. (C) 2020 IMSS. Published by Elsevier Inc.
引用
收藏
页码:1 / 14
页数:14
相关论文
共 50 条
  • [21] Calcium signaling and neurodegenerative diseases
    Bezprozvanny, Ilya
    TRENDS IN MOLECULAR MEDICINE, 2009, 15 (03) : 89 - 100
  • [22] RhoA Signaling in Neurodegenerative Diseases
    Schmidt, Sissel Ida
    Blaabjerg, Morten
    Freude, Kristine
    Meyer, Morten
    CELLS, 2022, 11 (09)
  • [23] The involvement of microRNAs in neurodegenerative diseases
    Maciotta, Simona
    Meregalli, Mirella
    Torrente, Yvan
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2013, 7
  • [24] Neuronal autophagy and neurodegenerative diseases
    Son, Jin H.
    Shim, Jung Hee
    Kim, Kyung-Hee
    Ha, Ji-Young
    Han, Ji Young
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2012, 44 (02): : 89 - 98
  • [25] The role of ferroptosis in neurodegenerative diseases
    Yunfei Xu
    Jie Zhao
    Yao Zhao
    Lin Zhou
    Haoduo Qiao
    Qing Xu
    Ying Liu
    Molecular Biology Reports, 2023, 50 : 1655 - 1661
  • [26] Mitophagy Regulates Neurodegenerative Diseases
    Cen, Xufeng
    Zhang, Manke
    Zhou, Mengxin
    Ye, Lingzhi
    Xia, Hongguang
    CELLS, 2021, 10 (08)
  • [27] Eye movements in neurodegenerative diseases
    MacAskill, Michael R.
    Anderson, Tim J.
    CURRENT OPINION IN NEUROLOGY, 2016, 29 (01) : 61 - 68
  • [28] Neuronal Mitophagy in Neurodegenerative Diseases
    Martinez-Vicente, Marta
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2017, 10
  • [29] Nuclear receptors in neurodegenerative diseases
    Skerrett, Rebecca
    Malm, Tarja
    Landreth, Gary
    NEUROBIOLOGY OF DISEASE, 2014, 72 : 104 - 116
  • [30] Potential Mechanisms Involved in the Prevention of Neurodegenerative Diseases by Lithium
    Camins, Antoni
    Verdaguer, Ester
    Junyent, Felix
    Yeste-Velasco, Marc
    Pelegri, Carme
    Vilaplana, Jordi
    Pallas, Merce
    CNS NEUROSCIENCE & THERAPEUTICS, 2009, 15 (04) : 333 - 344